These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 15621739)

  • 1. Arginine supplementation improves rotorod performance in sickle transgenic mice.
    Fasipe FR; Ubawike AE; Eva R; Fabry ME
    Hematology; 2004 Aug; 9(4):301-5. PubMed ID: 15621739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity.
    Romero JR; Suzuka SM; Nagel RL; Fabry ME
    Blood; 2002 Feb; 99(4):1103-8. PubMed ID: 11830454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of vascular instability in a transgenic mouse model of sickle cell disease.
    Nath KA; Shah V; Haggard JJ; Croatt AJ; Smith LA; Hebbel RP; Katusic ZS
    Am J Physiol Regul Integr Comp Physiol; 2000 Dec; 279(6):R1949-55. PubMed ID: 11080057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A second generation transgenic mouse model expressing both hemoglobin S (HbS) and HbS-Antilles results in increased phenotypic severity.
    Fabry ME; Sengupta A; Suzuka SM; Costantini F; Rubin EM; Hofrichter J; Christoph G; Manci E; Culberson D; Factor SM; Nagel RL
    Blood; 1995 Sep; 86(6):2419-28. PubMed ID: 7662990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protective effect of arginine on oxidative stress in transgenic sickle mouse models.
    Dasgupta T; Hebbel RP; Kaul DK
    Free Radic Biol Med; 2006 Dec; 41(12):1771-80. PubMed ID: 17157180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo demonstration of red cell-endothelial interaction, sickling and altered microvascular response to oxygen in the sickle transgenic mouse.
    Kaul DK; Fabry ME; Costantini F; Rubin EM; Nagel RL
    J Clin Invest; 1995 Dec; 96(6):2845-53. PubMed ID: 8675655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.
    Taylor CM; Kasztan M; Sedaka R; Molina PA; Dunaway LS; Pollock JS; Pollock DM
    Am J Physiol Regul Integr Comp Physiol; 2021 May; 320(5):R630-R640. PubMed ID: 33624556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A transgenic mouse model of hemoglobin S Antilles disease.
    Popp RA; Popp DM; Shinpock SG; Yang MY; Mural JG; Aguinaga MP; Kopsombut P; Roa PD; Turner EA; Rubin EM
    Blood; 1997 Jun; 89(11):4204-12. PubMed ID: 9166865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine glutathione S-transferase A1-1 in sickle transgenic mice.
    Ginzburg YZ; Andorfer JH; Rybicki AC; Fabry ME; Nagel RL
    Am J Hematol; 2007 Oct; 82(10):911-5. PubMed ID: 17617791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemolysis in sickle cell mice causes pulmonary hypertension due to global impairment in nitric oxide bioavailability.
    Hsu LL; Champion HC; Campbell-Lee SA; Bivalacqua TJ; Manci EA; Diwan BA; Schimel DM; Cochard AE; Wang X; Schechter AN; Noguchi CT; Gladwin MT
    Blood; 2007 Apr; 109(7):3088-98. PubMed ID: 17158223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemoglobin S Antilles: a variant with lower solubility than hemoglobin S and producing sickle cell disease in heterozygotes.
    Monplaisir N; Merault G; Poyart C; Rhoda MD; Craescu C; Vidaud M; Galacteros F; Blouquit Y; Rosa J
    Proc Natl Acad Sci U S A; 1986 Dec; 83(24):9363-7. PubMed ID: 3467311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quercetin Completely Ameliorates Hypoxia-Reoxygenation-Induced Pathophysiology Severity in NY1DD Transgenic Sickle Mice: Intrinsic Mild Steady State Pathophysiology of the Disease in NY1DD Is Also Reversed.
    Thangaswamy S; Branch CA; Ambadipudi K; Acharya SA
    Biomolecules; 2021 Oct; 11(10):. PubMed ID: 34680105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New therapies in sickle cell disease.
    Vichinsky E
    Lancet; 2002 Aug; 360(9333):629-31. PubMed ID: 12241949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockout-transgenic mouse model of sickle cell disease.
    Ryan TM; Ciavatta DJ; Townes TM
    Science; 1997 Oct; 278(5339):873-6. PubMed ID: 9346487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse models of sickle cell disease.
    Beuzard Y
    Transfus Clin Biol; 2008; 15(1-2):7-11. PubMed ID: 18502677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-induced in vivo sickling of transgenic mouse red cells.
    Rubin EM; Witkowska HE; Spangler E; Curtin P; Lubin BH; Mohandas N; Clift SM
    J Clin Invest; 1991 Feb; 87(2):639-47. PubMed ID: 1991848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Towards a transgenic mouse model of sickle cell disease: hemoglobin SAD.
    Trudel M; Saadane N; Garel MC; Bardakdjian-Michau J; Blouquit Y; Guerquin-Kern JL; Rouyer-Fessard P; Vidaud D; Pachnis A; Roméo PH
    EMBO J; 1991 Nov; 10(11):3157-65. PubMed ID: 1915288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease.
    Pászty C; Brion CM; Manci E; Witkowska HE; Stevens ME; Mohandas N; Rubin EM
    Science; 1997 Oct; 278(5339):876-8. PubMed ID: 9346488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transgenic mouse models of sickle cell disease.
    Beuzard Y
    Curr Opin Hematol; 1996 Mar; 3(2):150-5. PubMed ID: 9372066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Magnetic resonance evidence of hypoxia in a homozygous alpha-knockout of a transgenic mouse model for sickle cell disease.
    Fabry ME; Kennan RP; Paszty C; Costantini F; Rubin EM; Gore JC; Nagel RL
    J Clin Invest; 1996 Dec; 98(11):2450-5. PubMed ID: 8958206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.